Mental Health Care Provider's Perspectives Toward Adopting a Novel Technology to Improve Medication Adherence.
AuthorLiberman, Joshua N
JournalPsychiatric research and clinical practice
MetadataShow full item record
AbstractObjective: To understand perspectives of mental health care providers regarding barriers and drivers of adopting a medication ingestible event monitoring (IEM) system in clinical practice. Methods: Between April and October 2019, a cross-sectional, online survey was conducted among 131 prescribing clinicians and 119 non-prescribing clinicians providing care to patients with major depressive disorder, bipolar disorder, and schizophrenia. Results: Most prescribing clinicians were physicians (79.4%) while most non-prescribing clinicians (52.9%) were licensed clinical social workers, followed by counselors (30.8%), clinical psychologists (13.4%), and case managers (2.5%). Most respondents (93.2%) reported that clinicians can influence adherence, that the IEM technology was in their patients' best interest (63.6%), and a willingness to beta test the technology (54.8%). Support was positively associated with prescribing clinicians (OR: 2.2; 95% CI: 1.1, 4.5), belief that antipsychotics reduce the health, social, or financial consequences of the condition (OR: 3.8; 95% CI: 1.3, 11.0), concern for patients' well-being without monitoring (OR: 3.3; 95% CI: 1.2, 8.7), and belief the technology will enhance clinical alliance (OR: 3.1; 95% CI: 1.5, 6.3) or improve patient engagement (OR: 3.0; 95% CI: 1.5, 6.2). Support was inversely related to concerns about appropriate follow-up actions (OR: 0.4; 95% CI: 0.2, 0.9) and responsibilities (OR: 0.3; 95% CI: 0.1, 0.8) when using the technology. Conclusions: Our results suggest that IEM sensor technology adoption will depend upon additional evidence that patients will actively engage in the use of the technology, will benefit from the technology through improved outcomes, and that the additional burden placed upon providers is minimal compared to the potential benefit.
Rights/Terms© 2022 Otsuka Pharmaceutical Development & Commercialization, Inc. Psychiatric Research and Clinical Practice published by Wiley Periodicals LLC on behalf of American Psychiatric Association.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/20037
- Factors Influencing the Use of Second-Generation Antipsychotics in Children with Psychosis.
- Authors: Ramachandran S, Banahan BF 3rd, Bentley JP, West-Strum DS, Patel AS
- Issue date: 2016 Aug
- Prescriber Attitudes, Experiences, and Proclivities Toward Digital Medicine and How They Influence Adoption of Digital Medicine Platforms.
- Authors: Ruetsch C, Davis T, Liberman JN, Velligan DI, Robinson D, Jaeger C, Carpenter W, Forma F
- Issue date: 2021
- Are caregivers ready for digital? Caregiver preferences for health technology tools to monitor medication adherence among patients with serious mental illness.
- Authors: Forma F, Chiu K, Shafrin J, Boskovic DH, Veeranki SP
- Issue date: 2022 Jan-Dec
- Kentucky KASPER and Controlled Substance Prescribing.
- Authors: Dydyk AM, Sizemore DC, Smock W, Dulebohn SC, Porter BR
- Issue date: 2022 Jan
- Ingestible Sensors and Medication Adherence: Focus on Use in Serious Mental Illness.
- Authors: Alipour A, Gabrielson S, Patel PB
- Issue date: 2020 Jun 16